Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2026-04-29 Capital/Financing Update
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science annonce le succès d’un placement prive de 3,2 millions d’euros
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the successful completion of a private placement (augmentation de capital) raising €3.2 million, describes the terms of the share issuance, the new share count, admission to trading, use of proceeds, and lock-up arrangements. It is not a full financial report but a financing activity update focused on capital structure and fundraising. This clearly falls under a Capital/Financing Update.
2026-04-29 French
AB Science announces the successful completion of a EUR 3.2 million private placement
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the successful completion of a private placement capital increase of EUR 3.2 million, detailing terms, share issuance, warrants, use of proceeds, shareholding impact, and trading admission. This is a financing activity (fundraising) and capital structure change. It fits the “Capital/Financing Update” category.
2026-04-29 English
AB Science annonce un accord final sur la renégociation des modalités de remboursement de ses emprunts avec l’ensemble de ses créanciers financiers
Capital/Financing Update Classification · 1% confidence The document is a press release announcing and detailing a definitive agreement with financial creditors to restructure and defer loan repayments (PGE, Bpifrance innovation loan, BEI Covid loan), including maturity extensions and interest adjustments. This is an update on the company’s financing and capital structure rather than a shareholder vote, management change, dividend notice, or full annual/interim report. Therefore it falls under Capital/Financing Update (CAP).
2026-04-27 French
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the renegotiation of repayment terms of AB Science’s loans with its financial creditors, detailing deferral periods, maturity extensions, and interest-rate adjustments. This clearly pertains to the company’s debt and capital structure. It is not an annual or interim report, audit, or voting announcement, but a financing update. Therefore, it falls under Capital/Financing Update (CAP).
2026-04-27 English
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
Regulatory Filings Classification · 0% confidence The document is a corporate press release announcing the publication of a new scientific article on a preprint server (medRxiv). It contains no financial results, no management changes, no share transactions, no dividend announcements, nor any structured regulatory form. It does not fit categories like Earnings Release (ER), Investor Presentation (IP), or Report Publication Announcement (RPA) (which refers to company reports like annual/interim reports). Therefore, it defaults to the miscellaneous Regulatory Filings category (RNS).
2026-04-20 English
AB Science : Nouvelle publication sur medrxiv démontrant des bénéfices substantiels en termes de survie et de qualité de vie préservée avec le masitinib chez les patients atteints de SLA
Regulatory Filings Classification · 1% confidence The document is an AB Science press release announcing the publication of a new scientific article on the medRxiv preprint server. It contains clinical trial results and commentary by investigators. It is not an earnings release, financial report, or investor presentation, nor does it relate to management changes, dividends, or share transactions. It does not qualify as a company report publication announcement (RPA) because the content is a scientific paper rather than a corporate report. Therefore, it falls into the fallback category of Regulatory Filings (RNS) for miscellaneous corporate announcements.
2026-04-20 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.